Omar Mahmoud
Pulmonary Disease · Lewes, DENPI 1609362748
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,500 of the $1,679 with a category attached, or 89.3%. It is spread thinly across 22 manufacturers, the largest accounting for just 23.6% — the pattern of someone who eats at a lot of different presentations.
Across 54 payments — averaging $31.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$396
- Sanofi-aventis U.S. LLC$179
- Lilly USA, LLC$172
- Sanofi$167
- ANI Pharmaceuticals, Inc.$94
- Harmony Biosciences LLC$93
- plus $579 from 16 others
What the payments were for
- Food & beverage$1,50089%
- Education$17911%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 11 | $396 |
| Sanofi-aventis U.S. LLC | 2 | $179 |
| Lilly USA, LLC | 4 | $172 |
| Sanofi | 6 | $167 |
| ANI Pharmaceuticals, Inc. | 3 | $94 |
| Harmony Biosciences LLC | 3 | $93 |
| Verona Pharma, Inc. | 4 | $74 |
| Viatris Specialty LLC | 3 | $68 |
| AbbVie | 3 | $63 |
| Insmed, Inc. | 3 | $44 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $39 |
| Merck | 1 | $33 |
| Genentech USA, Inc. | 1 | $32 |
| Viiv Healthcare Company | 1 | $32 |
| Aimmune Therapeutics, Inc. | 1 | $30 |
| Grifols USA, LLC | 1 | $30 |
| Axsome Therapeutics, Inc. | 1 | $27 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $25 |
| Gilead | 1 | $25 |
| United Therapeutics Corporation | 1 | $22 |
| GSK | 1 | $21 |
| Electromed, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,679 in reported general payments places this provider in the 60th percentile of 39 pulmonary disease providers in Delaware.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $17,760 |
| SymbicortBudesonide/Formoterol Fumarate | 14 | $4,271 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 29 | $733 |
| Montelukast Sodium | 27 | $395 |
| Prednisone | 11 | $23 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $21 | $17,76024 claims |
| AstraZenecaSymbicort | $396 | $4,27114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 39 pulmonary disease providers in Delaware.
Other pulmonary disease in Lewes
- Victor BanzonLewes$300K
- Vikas BatraLewes$17K
- Ercilia AriasLewes$11K
- Samih RaadLewes$9K
- Albert RizzoNewark$162K
- Michel SamahaMilford$94K
- Haroon RajaNewark$44K
- Ismael MatusNewark$27K
- David JawaharDover$9K
- Anthony VasileWilmington$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.